Preview

Medical alphabet

Advanced search

Urine microbiota of urology department patients (pilot study)

https://doi.org/10.33667/2078-5631-2025-29-30-34

Abstract

Introduction. Urological hospitals represent a special clinical and epidemiological environment with a high risk of the formation of multidrugresistant strains of uropathogens. Research in the field of investigating the characteristics of urological microbiota is of primary importance for

the development of empirical therapy protocols and the improvement of clinical outcomes.

Objective. To investigate the microbiological spectrum and antibiotic resistance of microorganisms isolated from the urine of patients in the urology department.

Materials and Methods. A pilot study was conducted at the FSBI Central Research Institute of Epidemiology of Rospotrebnadzor from April to September 2025.

A total of 130 midstream urine samples were studied from patients of the urology department of the Research Center of Surgery named after Academician B. V. Petrovsky (79 men, 51 women, median age – 57 years). Standard bacteriological methods were used with microorganism identification by MALDI-TOF MS and antibiotic susceptibility testing by the minimum inhibitory concentration (MIC) assessment method according to EUCAST standards.

Results. Microorganism growth was detected in 28.5 % of samples. The dominant pathogens were: Escherichia coli (42.5 %), Enterococcus faecalis (17.5 %), Klebsiella pneumoniae (12.5 %), Staphylococcus aureus, Proteus mirabilis, and Streptococcus agalactiae (5 % each). Escherichia coli showed high resistance to ciprofloxacin (47.1 %) and ampicillin (52.9 %) with preserved 100 % sensitivity to amikacin and fosfomycin. Klebsiella pneumoniae was characterized by pronounced multidrug resistance to most β-lactam antibiotics, sulfonamides, and fluoroquinolones with preserved sensitivity to colistin (100 %). Enterococcus faecalis maintained sensitivity to traditional drugs (ampicillin, vancomycin).

Conclusion. High levels of antibiotic resistance were identified among major uropathogens, especially to fluoroquinolones and β-lactam antibiotics. The preserved activity of amikacin, fosfomycin, and colistin makes these drugs priorities for treating resistant infections in this patient population.

About the Authors

V. M. Kulikov
ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора
Russian Federation

Kulikov Vladimir M., graduate student

Moscow



T. V. Tronza
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation

Tronza Tatyana V., head of Laboratory Research at Laboratory of Clinical Microbiology and Human Microbial Ecology

Moscow



G. A. Koval
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation

Koval Galina A., bacteriologist at Laboratory of Clinical Microbiology and Human Microbial Ecology

Moscow



N. M. Gogolev
B. V. Petrovsky Russian Scientific Center of Surgery
Russian Federation

Gogolev Nikolai M., urologist at Urology Dept, Scientific and Clinical Center No. 2

Moscow



S. V. Korolev
B. V. Petrovsky Russian Scientific Center of Surgery
Russian Federation

Korolev Sergey V., PhD Med, senior researcher, head of Urology Dept of Scientific and Clinical Center No. 2

Moscow



I. I. Eremin
B. V. Petrovsky Russian Scientific Center of Surgery
Russian Federation

Eremin Ilya I., deputy director for Research

Moscow



T. S. Skachkova
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation

Skachkova Tatyana S., PhD Med, acting head of Laboratory of Molecular Diagnostics and Epidemiology of Reproductive Organ Infections

Moscow



E. M. Kulikova
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation

Kulikova Elena M., resident

Moscow



K. V. Kotenko
B. V. Petrovsky Russian Scientific Center of Surgery
Russian Federation

Kotenko Konstantin V., Dr Med Sci (habil.), professor, RAS academicia, Honored Doctor of the Russian Federation, director of the State Scientific Center of the Russian Federation

Moscow



V. G. Akimkin
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation

Akimkin Vasily G., Dr Med Sci (habil.), professor, RAS academician, director

Moscow



References

1. Aragon I. M., Herrera-Imbroda B., Queipo-Ortuno M. I. et al. The Urinary Tract Microbiome in Health and Disease. European urology focus. 2018 Jan;4 (1): 128–138. DOI: 10.1016/j.euf.2016.11.001

2. Nelson D. E., Van Der Pol B., Dong Q., et al. Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection // PLoS One 2010 Nov 24; 5 (11): e14116. DOI: 10.1371/journal.pone.0014116

3. Siddiqui H., Nederbragt A. J., Lagesen K., et al. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons // BMC Microbiol 2011; Nov 2: 11: 244. DOI: 10.1186/1471-2180-11-244

4. Flores-Mireles A.L., Walker J. N., Caparon M., Hultgren S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options // Nat Rev Microbiol 2015 May; 13 (5): 269–84. DOI: 10.1038/nrmicro3432. Epub 2015 Apr 8

5. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021. Geneva: WHO; 2021.

6. Rafal'skiy V.V., Dovgan E. V. Fluoroquinolones in the treatment of urinary tract infections: the role of antibiotic resistance // RMZh. 2011; 16: 1006. (In Russ.).

7. El bouamri M.C., Arsalane L., Kamouni Y., Yahyaoui H., Bennouar N., Berraha M., Zouhair S. // Profil actuel de résistance aux antibiotiques des souches d’Escherichia coli uropathogènes et conséquences thérapeutiques // Progrès en Urologie Volume 24, Issue 16, December 2014, Pages 1058–1062

8. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. // Emerg Infect Dis. 2011; 17 (10): 1791–1798

9. European Association of Urology. Guidelines on urological infections. Arnhem, The Netherlands: EAU Guidelines Office; 2023.

10. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. // Lancet. 2022; 399 (10325): 629–655.

11. Filippova E. S., Bazhenov I. V., Zyryanov A. V., Amineva P. G. Species diversity of the urine microbiome in patients with neurogenic bladder is associated with a lower risk of recurrence of urinary tract infection // Experimental and Clinical Urology 2024; 17 (3): 140–147. (In Russ.). https://doi.org/10.29188/2222-8543-2024-17-3-140-147

12. Naboka Yu.L., Rymashevsky A. N., Kogan M. I., Gudima I. A., Borovleva O. A., Dzhalagoniya K. T., Zarutsky S. A. Microbiota of urine and vagina of healthy postmenopausal women (pilot study) // Urology 2016; 1: 18–24. (In Russ.).

13. Kadyrov Z. A., Stepanov V. N., Faniev M. V., Ramishvili Sh. V. Microbiota of urogenital organs // Urology 2020; 1. (In Russ.). https://dx.doi.org/10.18565/urology.2020.1.116–120

14. Rafal'sky V.V., Kryukova N. O., Korenev D. S. Resistance of pathogens causing community-acquired urinary tract infections: lessons from Russian multicenter microbiological studies // Urology 2020; 4. (In Russ.). https://dx.doi.org/10.18565/urology.2020.4.124–130

15. Naboka Yu.L., Gudima I. A., Mitusova E. V., Bejanyan S. K., Morgun P. P., Kogan M. I., Dzhalagoniya K. T., Akimenko M. A. Resistance of uropathogens to antibacterial drugs in patients with acute obstructive pyelonephritis // Urology 2017; 4. (In Russ.). https://dx.doi.org/10.18565/urol.2017.4.27–31

16. Kranz J., Bartoletti R., Bruyère F., et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines // Eur Urol. 2024 Jul; 86 (1): 27–41. DOI: 10.1016/j.eururo.2024.03.035.

17. Naboka Yu.L., Khasigov A. V., Khazhokov M. A., Belousov I. I., Gudima I. A., Ilyash A. V., Kogan M. I. Urine microbiota before and after lithotripsy for kidney stones // Bulletin of Urology No. 3/2013 pp. 20–24. (In Russ.).

18. Zaitseva E. A., Luchaninova V. N., Melnikova E. A., Komenkova T. S., Krukovich E. V. Clinical and microbiological aspects of urinary tract infection associated with Enterococcus faecalis // Infection and Immunity 2021; 1: 184–190. (In Russ.).


Review

For citations:


Kulikov V.M., Tronza T.V., Koval G.A., Gogolev N.M., Korolev S.V., Eremin I.I., Skachkova T.S., Kulikova E.M., Kotenko K.V., Akimkin V.G. Urine microbiota of urology department patients (pilot study). Medical alphabet. 2025;(29):30-34. (In Russ.) https://doi.org/10.33667/2078-5631-2025-29-30-34

Views: 159

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)